Zobrazeno 1 - 6
of 6
pro vyhledávání: '"JJ Alcaraz Sanchez"'
Autor:
A Melgarejo-Ortuño, JJ Alcaraz Sanchez, CA Apezteguia Fernández, MDP Bautista Sanz, C de Caceres Velasco, E Matilla Garcia, B Rodriguez Vargas, MA Amor Garcia, R Moreno Diaz
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52168f37b91c30b389ca472276fb7613
https://doi.org/10.1136/ejhpharm-2022-eahp.176
https://doi.org/10.1136/ejhpharm-2022-eahp.176
Autor:
JJ Alcaraz Sanchez, A Pintado Alvarez, JC Del Río Valencia, B Mora Rodríguez, I Muñoz Castillo
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with epidermal growth factor receptor (EG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab47193323cf24a885680cb30c40c7e9
https://doi.org/10.1136/ejhpharm-2021-eahpconf.108
https://doi.org/10.1136/ejhpharm-2021-eahpconf.108
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Colorectal cancer represents a major health problem in developed countries. The incidence increases with age. Median age at diagnosis is about 70 years. This creates new needs in the treatment antineoplastic, considering the characteristic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cf53e8d3658ffb28cd2cede4b808baf
https://doi.org/10.1136/ejhpharm-2019-eahpconf.253
https://doi.org/10.1136/ejhpharm-2019-eahpconf.253
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Nowadays, there is a stronger consensus on the proceedings of nutritional support with parenteral nutrition (PN) in paediatrics and nutritional requirements in order to improve the process quality and the patient’s safety. Purpose Review
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebf7823fb4d7d5d7bc4f95cafa91c1a4
https://doi.org/10.1136/ejhpharm-2019-eahpconf.338
https://doi.org/10.1136/ejhpharm-2019-eahpconf.338
Publikováno v:
Eur J Hosp Pharm
Background Takayasu arteritis (TA) is a chronic inflammatory vasculitis of unknown origin affecting large vessels, predominantly the aorta and its main branches. Early symptoms include systemic inflammation and ischaemia of involved organs. It was th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::189a05e9cb51b21966ab95f87daa9303
https://europepmc.org/articles/PMC7535324/
https://europepmc.org/articles/PMC7535324/
Publikováno v:
Eur J Hosp Pharm
Background Nivolumab is a human immunoglobulin G4 monoclonal antibody, which binds to the programmed death-1 receptor and blocks its interaction with PD-L1 and PD-L2. It is approved for melanoma, renal, urhotelial, non-small cell lung cancer (NSCLC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14ab9e79c215f9f7949519d24709d186
https://doi.org/10.1136/ejhpharm-2018-eahpconf.190
https://doi.org/10.1136/ejhpharm-2018-eahpconf.190